CytoDyn Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jacob Lalezari
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1111 Main Street Vancouver WA United States of America 98660
- IPO Date
- Dec 13, 2006
- CIK
- 0001175680
- Website
- cytodyn.com
- Similar Companies
- Business
- CytoDyn Inc. (CYDY) is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor for multiple therapeutic indications including solid-tumor oncology, infectious diseases, and inflammatory conditions; its pipeline encompasses Phase 2 trials for triple-negative breast cancer, metastatic colorectal cancer, metabolic dysfunction-associated steatohepatitis (MASH), chronic inflammation, acute and long COVID-19, and HIV antiviral therapy, with Phase 3 ongoing for HIV and preclinical efforts in glioblastoma, prostate cancer, Alzheimer's disease, HIV post-exposure prophylaxis, and stem cell transplantation for HIV cure. Founded in 2002 and headquartered in Vancouver, Washington, the company operates primarily in the United States with a strategic emphasis on oncology and immunology targeting patient populations suffering from cancers such as metastatic triple-negative breast cancer, inflammatory disorders, and HIV. In November 2025, CytoDyn secured a $30 million equity funding commitment from Yorkville Advisors Global to advance leronlimab programs, particularly research on PD-L1 upregulation, providing flexible capital over 36 months without minimum commitments or operational restrictions; recent milestones include FDA clearance for its Phase II oncology trial in late 2024 conducted with Syneos Health.
Company News
CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
CytoDyn to Host Investor Webcast
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
Kessler Topaz Meltzer & Check, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of CytoDyn Inc. common stock
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
CytoDyn to Present at the LD Micro Invitational XVI
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
CytoDyn to Host Investor Webcast
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
CytoDyn to Present at the AACR Annual Meeting 2026
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer